325 related articles for article (PubMed ID: 16412208)
1. Pathobiology of CD30+ cutaneous T-cell lymphomas.
Kadin ME
J Cutan Pathol; 2006 Feb; 33 Suppl 1():10-7. PubMed ID: 16412208
[TBL] [Abstract][Full Text] [Related]
2. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
3. Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
Greisser J; Palmedo G; Sander C; Kutzner H; Kazakov DV; Roos M; Burg G; Kempf W
J Cutan Pathol; 2006 Nov; 33(11):711-5. PubMed ID: 17083688
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis in CD30-positive lymphoproliferative disorders of the skin.
Greisser J; Doebbeling U; Roos M; Mueller B; Schmid M; Burg G; Kadin ME; Kempf W
Exp Dermatol; 2005 May; 14(5):380-5. PubMed ID: 15854132
[TBL] [Abstract][Full Text] [Related]
5. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.
Kempf W
J Cutan Pathol; 2006 Feb; 33 Suppl 1():58-70. PubMed ID: 16412214
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
7. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas.
Mao X; Orchard G; Russell-Jones R; Whittaker S
Br J Dermatol; 2007 Nov; 157(5):914-21. PubMed ID: 17725669
[TBL] [Abstract][Full Text] [Related]
8. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders.
De Souza A; Tinguely M; Pfaltz M; Burghart DR; Kempf W
J Cutan Pathol; 2014 Dec; 41(12):901-6. PubMed ID: 25353265
[TBL] [Abstract][Full Text] [Related]
9. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.
Paulli M; Berti E
Haematologica; 2004 Nov; 89(11):1372-88. PubMed ID: 15531460
[TBL] [Abstract][Full Text] [Related]
11. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
[TBL] [Abstract][Full Text] [Related]
12. Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical-characteristics.
Kaudewitz P; Stein H; Dallenbach F; Eckert F; Bieber K; Burg G; Braun-Falco O
Am J Pathol; 1989 Aug; 135(2):359-67. PubMed ID: 2551170
[TBL] [Abstract][Full Text] [Related]
13. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.
Pham-Ledard A; Prochazkova-Carlotti M; Laharanne E; Vergier B; Jouary T; Beylot-Barry M; Merlio JP
J Invest Dermatol; 2010 Mar; 130(3):816-25. PubMed ID: 19812605
[TBL] [Abstract][Full Text] [Related]
14. Clusterin expression in cutaneous CD30-positive lymphoproliferative disorders and their histologic simulants.
Olsen SH; Ma L; Schnitzer B; Fullen DR
J Cutan Pathol; 2009 Mar; 36(3):302-7. PubMed ID: 19220628
[TBL] [Abstract][Full Text] [Related]
15. The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders.
Wasco MJ; Fullen D; Su L; Ma L
Hum Pathol; 2008 Apr; 39(4):557-63. PubMed ID: 18234282
[TBL] [Abstract][Full Text] [Related]
16. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.
Kim YC; Yang WI; Lee MG; Kim SN; Cho KH; Lee SJ; Lee MW; Koh JK
Int J Dermatol; 2006 Nov; 45(11):1312-6. PubMed ID: 17076712
[TBL] [Abstract][Full Text] [Related]
18. The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases.
Kapur S; Tiemann M; Menke MA; Schubert C; Parwaresch R
Indian J Med Res; 2005 Jan; 121(1):46-54. PubMed ID: 15713979
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous CD30+ lymphoproliferative disorder--a 10-year follow-up. A case report and differential diagnosis.
Szpor J; Dyduch G; Gałazka K; Bahyrycz J; Stój A; Tomaszewska R
Pol J Pathol; 2009; 60(1):43-8. PubMed ID: 19670703
[TBL] [Abstract][Full Text] [Related]
20. The protean spectrum of non-Hodgkin lymphomas with prominent involvement of subcutaneous fat.
Massone C; Lozzi GP; Egberts F; Fink-Puches R; Cota C; Kerl H; Cerroni L
J Cutan Pathol; 2006 Jun; 33(6):418-25. PubMed ID: 16776717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
